Nicole M. de Roos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nicole M. de Roos has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Ben J. M. Witteman
Department of Gastroenterology, Gelderse Vallei Hospital, Ede, The Netherlands
6 shared publications - Carlijn R. Lamers
Department of Gastroenterology and Hepatology, Hospital Gelderse Vallei, Ede, The Netherlands
3 shared publications - Erwin Gerard Zoetendal
Laboratory of Microbiology, Wageningen University & Research, Wageningen, The Netherlands
3 shared publications - Iris Rijnaarts
WholeFiber Holding BV
3 shared publications - Nicole de Wit
Food and Health Group, Wageningen Food and Biobased Research, Wageningen University and Research
3 shared publications - Anna Willemina Nap
Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, Gelderland, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- p. 1-10
Impact of 3-d turmeric supplementation on fasting and postprandial lipopolysaccharide and chylomicron-related markers in patients with irritable bowel syndrome: a randomised crossover trial
Lipopolysaccharide (LPS) has been implicated in increased gut permeability and low-grade mucosal inflammation, conditions that are linked to the pathophysiology of irritable bowel syndrome (IBS). Because increased dietary fat intake can both trigger IBS symptoms and promote LPS translocation in the gut, this study aimed to better understand how a turmeric formula (TF) affects fasting and postprandial LPS response, after a high-fat challenge in patients with IBS (primary outcome). Secondary outcomes included postprandial Apo-B48 and TAG as markers of chylomicron-mediated LPS translocation, as well as gastrointestinal (GI) symptoms and stool pattern. In this randomised, double-blind, placebo-controlled crossover trial, eighteen patients with IBS completed two high-fat challenge tests after 3-d supplementation with either 300 mg TF or placebo. Blood was collected in the fasting state and up to 5 h postprandially. Data were analysed using repeated-measures mixed models. TF did not significantly alter postprandial LPS levels compared with placebo but significantly reduced postprandial Apo-B48 and TAG (mean ratios 0·82 and 0·87, p = 0·04 and p = 0·01, respectively). Fasting LPS and TAG showed a non-significant reduction after TF (mean ratios 0·79 and 0·87; both p = 0·06, respectively). No differences were observed in GI symptoms or stool characteristics. To conclude, TF did not influence dietary fat-mediated LPS translocation, but it reduced postprandial chylomicron markers, indicating a potential attenuation of chylomicron-mediated postprandial inflammation. Together with the observed trend towards reduced fasting LPS levels, these findings suggest that TF might have beneficial effects on low-grade subclinical inflammation, which could be relevant for IBS patients.
- 3 August 2026
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- p. 1-10
Open AccessImpact of 3-d turmeric supplementation on fasting and postprandial lipopolysaccharide and chylomicron-related markers in patients with irritable bowel syndrome: a randomised crossover trial
Lipopolysaccharide (LPS) has been implicated in increased gut permeability and low-grade mucosal inflammation, conditions that are linked to the pathophysiology of irritable bowel syndrome (IBS). Because increased dietary fat intake can both trigger IBS symptoms and promote LPS translocation in the gut, this study aimed to better understand how a turmeric formula (TF) affects fasting and postprandial LPS response, after a high-fat challenge in patients with IBS (primary outcome). Secondary outcomes included postprandial Apo-B48 and TAG as markers of chylomicron-mediated LPS translocation, as well as gastrointestinal (GI) symptoms and stool pattern. In this randomised, double-blind, placebo-controlled crossover trial, eighteen patients with IBS completed two high-fat challenge tests after 3-d supplementation with either 300 mg TF or placebo. Blood was collected in the fasting state and up to 5 h postprandially. Data were analysed using repeated-measures mixed models. TF did not significantly alter postprandial LPS levels compared with placebo but significantly reduced postprandial Apo-B48 and TAG (mean ratios 0·82 and 0·87, p = 0·04 and p = 0·01, respectively). Fasting LPS and TAG showed a non-significant reduction after TF (mean ratios 0·79 and 0·87; both p = 0·06, respectively). No differences were observed in GI symptoms or stool characteristics. To conclude, TF did not influence dietary fat-mediated LPS translocation, but it reduced postprandial chylomicron markers, indicating a potential attenuation of chylomicron-mediated postprandial inflammation. Together with the observed trend towards reduced fasting LPS levels, these findings suggest that TF might have beneficial effects on low-grade subclinical inflammation, which could be relevant for IBS patients.
- Open Access
- 22 August 2025
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 94 (2) , e70145
Menstrual Effluent Derived Immune Cell Composition Is Distinct in Women Using Contraceptives: A Pilot Study
Problem: Menstrual effluent (ME) is widely used to study immune‐related reproductive disorders. However, women using contraceptives are often excluded from such studies due to limited knowledge of their impact on the endometrial immune cell composition. This gap in knowledge restricts our ability to include women using contraceptives in the scientific investigations and account for potential immunological variations associated with contraceptive use. Therefore, we aim to investigate whether contraceptive use is associated with differences in the uterine immune system.Method of Study: ME was collected from women using combined oral contraceptives (COC, n = 5), a copper intrauterine device (IUD, n = 3), or no contraceptives (n = 5). Immune cells were isolated from ME and analyzed using flow‐cytometry. Data were analyzed using an unpaired t‐test, followed by multiple testing correction using the false discovery rate (FDR) method.Results: Women using COCs exhibited a marked reduction in the frequency of the immunoregulatory CD56brightCD16− endometrial Natural Killer (eNK) cells compared to women using no contraceptives (30.1% ± 5.99 and 66.0% ± 10.6; p = 0.001). Additionally, women using copper IUD showed elevated frequencies of proliferating Ki‐67+CD8+ T cells compared to COC users and controls (19.8% ± 4.3, 2.69% ± 1.23, and 3.77% ± 4.4).Conclusions: This pilot study highlights the importance of considering contraceptive use when studying immune‐related reproductive problems.
- 22 August 2025
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 94 (2) , e70145
Open AccessMenstrual Effluent Derived Immune Cell Composition Is Distinct in Women Using Contraceptives: A Pilot Study
Problem: Menstrual effluent (ME) is widely used to study immune‐related reproductive disorders. However, women using contraceptives are often excluded from such studies due to limited knowledge of their impact on the endometrial immune cell composition. This gap in knowledge restricts our ability to include women using contraceptives in the scientific investigations and account for potential immunological variations associated with contraceptive use. Therefore, we aim to investigate whether contraceptive use is associated with differences in the uterine immune system.Method of Study: ME was collected from women using combined oral contraceptives (COC, n = 5), a copper intrauterine device (IUD, n = 3), or no contraceptives (n = 5). Immune cells were isolated from ME and analyzed using flow‐cytometry. Data were analyzed using an unpaired t‐test, followed by multiple testing correction using the false discovery rate (FDR) method.Results: Women using COCs exhibited a marked reduction in the frequency of the immunoregulatory CD56brightCD16− endometrial Natural Killer (eNK) cells compared to women using no contraceptives (30.1% ± 5.99 and 66.0% ± 10.6; p = 0.001). Additionally, women using copper IUD showed elevated frequencies of proliferating Ki‐67+CD8+ T cells compared to COC users and controls (19.8% ± 4.3, 2.69% ± 1.23, and 3.77% ± 4.4).Conclusions: This pilot study highlights the importance of considering contraceptive use when studying immune‐related reproductive problems.
- Open Access
- 11 July 2025
- Published by Cambridge University Press (CUP) in Journal of Nutritional Science
- Vol. 14, e46
Randomised controlled trial: nutritional supplements to relieve irritable bowel syndrome symptoms by targeting the gut microbiota
In individuals with irritable bowel syndrome (IBS), eliminating dietary triggers can alleviate symptoms but may lead to nutrient deficiencies and overall health decline. Although various nutritional supplements show promising results in relieving IBS symptoms due to their potential to alter the microbiome, conclusive scientific evidence remains lacking. This exploratory study aims to assess the bifidogenic properties of four nutritional supplement interventions and their impact on IBS-symptoms, faecal microbiota composition, faecal short-chain fatty acid (SCFA) concentrations, stool pattern, and quality of life (QoL), compared to a placebo control. Seventy subjects with IBS, meeting the ROME IV criteria, participated in this randomised, double-blind, placebo-controlled parallel intervention study. Subjects were assigned to one of the four treatment groups, receiving either resistant starch, pea fibre, chondroitin sulfate, protein hydrolysate, or placebo daily for four weeks. Daily reports on stool pattern and gastrointestinal complaints were collected. Stool samples and questionnaires on dietary intake, symptom severity, QoL, and anxiety and depression were collected at baseline and after the 4-week intervention. The results show no significant increase in Bifidobacterium abundance or faecal SCFA levels after the 4-week intervention with any of the four nutritional supplement interventions. While some improvements in symptom severity and QoL were observed within-groups, these were not significantly different from changes observed with placebo. In conclusion, the tested nutritional supplements did not increase Bifidobacterium abundance in subjects with IBS within four weeks. Furthermore, we conclude that future studies should consider a run-in period and a larger sample size to study improvements in IBS symptoms.
- 11 July 2025
- Published by Cambridge University Press (CUP) in Journal of Nutritional Science
- Vol. 14, e46
Open AccessRandomised controlled trial: nutritional supplements to relieve irritable bowel syndrome symptoms by targeting the gut microbiota
In individuals with irritable bowel syndrome (IBS), eliminating dietary triggers can alleviate symptoms but may lead to nutrient deficiencies and overall health decline. Although various nutritional supplements show promising results in relieving IBS symptoms due to their potential to alter the microbiome, conclusive scientific evidence remains lacking. This exploratory study aims to assess the bifidogenic properties of four nutritional supplement interventions and their impact on IBS-symptoms, faecal microbiota composition, faecal short-chain fatty acid (SCFA) concentrations, stool pattern, and quality of life (QoL), compared to a placebo control. Seventy subjects with IBS, meeting the ROME IV criteria, participated in this randomised, double-blind, placebo-controlled parallel intervention study. Subjects were assigned to one of the four treatment groups, receiving either resistant starch, pea fibre, chondroitin sulfate, protein hydrolysate, or placebo daily for four weeks. Daily reports on stool pattern and gastrointestinal complaints were collected. Stool samples and questionnaires on dietary intake, symptom severity, QoL, and anxiety and depression were collected at baseline and after the 4-week intervention. The results show no significant increase in Bifidobacterium abundance or faecal SCFA levels after the 4-week intervention with any of the four nutritional supplement interventions. While some improvements in symptom severity and QoL were observed within-groups, these were not significantly different from changes observed with placebo. In conclusion, the tested nutritional supplements did not increase Bifidobacterium abundance in subjects with IBS within four weeks. Furthermore, we conclude that future studies should consider a run-in period and a larger sample size to study improvements in IBS symptoms.
- Open Access
- 15 March 2024
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 34 (5) , 454-462
The Effect of Niacinamide Supplementation on Phosphate Concentrations in Dutch Dialysis Patients: A Randomized Crossover Trial
- 15 March 2024
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 34 (5) , 454-462
Open AccessThe Effect of Niacinamide Supplementation on Phosphate Concentrations in Dutch Dialysis Patients: A Randomized Crossover Trial
- Open Access
- 18 October 2023
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 48 (2) , 103624
The feasibility of an anti-inflammatory diet in endometriosis: barriers and facilitators perceived by endometriosis patients
- 18 October 2023
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 48 (2) , 103624
Open AccessThe feasibility of an anti-inflammatory diet in endometriosis: barriers and facilitators perceived by endometriosis patients
- 23 May 2023
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Correcting metabolic acidosis and the nutritional status of patients with non-dialysis dependent chronic kidney disease: a systematic review and meta-analysis
Review question / Objective: What is the effect of correcting metabolic acidosis on different nutritional status parameters in patients with CKD. Information sources: The search was conducted in MEDLINE and the Cochrane Library from inception to December 2022. Two investigators extracted the data independently. Titles and abstracts were screened based on predefined inclusion and exclusion criteria in the protocol. Similarly, full-text articles were screened using a predefined form to extract data. These included year of publication, study design and setting, population characteristics, description of intervention and control conditions, number of patients, and baseline and follow-up outcomes of interest. We requested any relevant missing information from original study authors and received the raw data from one author.
- 23 May 2023
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Correcting metabolic acidosis and the nutritional status of patients with non-dialysis dependent chronic kidney disease: a systematic review and meta-analysis
Review question / Objective: What is the effect of correcting metabolic acidosis on different nutritional status parameters in patients with CKD. Information sources: The search was conducted in MEDLINE and the Cochrane Library from inception to December 2022. Two investigators extracted the data independently. Titles and abstracts were screened based on predefined inclusion and exclusion criteria in the protocol. Similarly, full-text articles were screened using a predefined form to extract data. These included year of publication, study design and setting, population characteristics, description of intervention and control conditions, number of patients, and baseline and follow-up outcomes of interest. We requested any relevant missing information from original study authors and received the raw data from one author.
- Open Access
- 1 August 2022
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 7 (4) , 436-444
Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing
Background: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders. Its pathophysiology is diverse and variable, involving disturbed gut–brain interactions, altered motility and secretion, visceral hypersensitivity, increased intestinal permeability, immune activation, and changes in gut microbiota. Complaints experienced by patients suffering from IBS and its co-morbidities strongly impair quality of life (QoL), and available treatments are often unsatisfactory. Anecdotal reports and preclinical data suggest that the endocannabinoid system and functionally related mechanisms could offer treatment targets. Cannabidiol (CBD) is a candidate agent of interest with a broad molecular target profile and the absence of psychoactive properties. Materials and Methods: In 32 female IBS patients, we explored the effect of a chewing gum formulation containing 50 mg CBD on abdominal pain and perceived well-being in a randomized, double-blinded, placebo-controlled cross-over trial. Chewing gums were used on-demand guided by pain symptoms with a maximum of six per day. Pain intensity was assessed by a visual analogue scale (scale 0.0–10.0), and QoL was evaluated with the IBS-36 questionnaire. Results: There was no statistically significant difference in pain scores between CBD and placebo at a group level. Subgroup and individual analyses showed a highly variable picture. No indications were found for symptom-driven intake, which also remained lower than expected overall. Conclusions: With the current design, based on the assumption that IBS patients would adjust their intake to their perceived symptom relief, no differences at the group level were found between CBD and placebo gum in pain scores and the number of gums used. The low use of the gums also indicates that the benefits experienced by these patients generally did not outweigh practical disadvantages such as prolonged chewing throughout the day. The very high intra- and inter-individual variation in IBS symptoms warrant future trials that are more personalized, for example by applying an N-of-1 (rotating) design with individualized dose titration.
- 1 August 2022
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 7 (4) , 436-444
Open AccessEffects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing
Background: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders. Its pathophysiology is diverse and variable, involving disturbed gut–brain interactions, altered motility and secretion, visceral hypersensitivity, increased intestinal permeability, immune activation, and changes in gut microbiota. Complaints experienced by patients suffering from IBS and its co-morbidities strongly impair quality of life (QoL), and available treatments are often unsatisfactory. Anecdotal reports and preclinical data suggest that the endocannabinoid system and functionally related mechanisms could offer treatment targets. Cannabidiol (CBD) is a candidate agent of interest with a broad molecular target profile and the absence of psychoactive properties. Materials and Methods: In 32 female IBS patients, we explored the effect of a chewing gum formulation containing 50 mg CBD on abdominal pain and perceived well-being in a randomized, double-blinded, placebo-controlled cross-over trial. Chewing gums were used on-demand guided by pain symptoms with a maximum of six per day. Pain intensity was assessed by a visual analogue scale (scale 0.0–10.0), and QoL was evaluated with the IBS-36 questionnaire. Results: There was no statistically significant difference in pain scores between CBD and placebo at a group level. Subgroup and individual analyses showed a highly variable picture. No indications were found for symptom-driven intake, which also remained lower than expected overall. Conclusions: With the current design, based on the assumption that IBS patients would adjust their intake to their perceived symptom relief, no differences at the group level were found between CBD and placebo gum in pain scores and the number of gums used. The low use of the gums also indicates that the benefits experienced by these patients generally did not outweigh practical disadvantages such as prolonged chewing throughout the day. The very high intra- and inter-individual variation in IBS symptoms warrant future trials that are more personalized, for example by applying an N-of-1 (rotating) design with individualized dose titration.
- Open Access
- 27 May 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (11) , 5137-5148
Fecal Microbiota Signatures Are Not Consistently Related to Symptom Severity in Irritable Bowel Syndrome
Background Irritable bowel syndrome (IBS) is the most prevalent functional bowel disorder, but its pathophysiology is still unknown. Although a microbial signature associated with IBS severity has been suggested, its association with IBS severity still remains largely unknown. Aims This study aims to assess longitudinal dynamics of fecal microbiota and short-chain fatty acids (SCFAs) in different IBS severity groups and study the association with stool pattern, diet, depression, anxiety, and quality of life (QoL). Methods A longitudinal study was performed, including n = 91 IBS patients and n = 28 matched controls. All participants collected fecal samples for microbiota composition and SCFA analysis and completed validated questionnaires regarding IBS severity, stool pattern, depression, anxiety, and IBS-QoL at two timepoints with four weeks in-between. Diet was assessed at the first timepoint. Results Over time, 36% of IBS patients changed in severity group, and 53% changed in predominant stool pattern. The largest proportion of microbiota variation was explained by the individual (R2 = 70.07%). Microbiota alpha diversity and composition, and SCFAs did not differ between IBS severity groups, nor between IBS and controls. Relative abundances of Bifidobacterium, Terrisporobacter, and Turicibacter consistently differed between IBS and controls, but not between IBS severity groups. Large dynamics over time were observed in the association of microbiota composition with questionnaire data where IBS symptom severity was associated at T1 but not at T2. Conclusions Fecal microbiota and SCFA signatures were not consistently associated with IBS severity over time, indicating the importance of repeated sampling in IBS research.
- 27 May 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (11) , 5137-5148
Open AccessFecal Microbiota Signatures Are Not Consistently Related to Symptom Severity in Irritable Bowel Syndrome
Background Irritable bowel syndrome (IBS) is the most prevalent functional bowel disorder, but its pathophysiology is still unknown. Although a microbial signature associated with IBS severity has been suggested, its association with IBS severity still remains largely unknown. Aims This study aims to assess longitudinal dynamics of fecal microbiota and short-chain fatty acids (SCFAs) in different IBS severity groups and study the association with stool pattern, diet, depression, anxiety, and quality of life (QoL). Methods A longitudinal study was performed, including n = 91 IBS patients and n = 28 matched controls. All participants collected fecal samples for microbiota composition and SCFA analysis and completed validated questionnaires regarding IBS severity, stool pattern, depression, anxiety, and IBS-QoL at two timepoints with four weeks in-between. Diet was assessed at the first timepoint. Results Over time, 36% of IBS patients changed in severity group, and 53% changed in predominant stool pattern. The largest proportion of microbiota variation was explained by the individual (R2 = 70.07%). Microbiota alpha diversity and composition, and SCFAs did not differ between IBS severity groups, nor between IBS and controls. Relative abundances of Bifidobacterium, Terrisporobacter, and Turicibacter consistently differed between IBS and controls, but not between IBS severity groups. Large dynamics over time were observed in the association of microbiota composition with questionnaire data where IBS symptom severity was associated at T1 but not at T2. Conclusions Fecal microbiota and SCFA signatures were not consistently associated with IBS severity over time, indicating the importance of repeated sampling in IBS research.
- Open Access
- 28 April 2022
- Published by Cambridge University Press (CUP) in Journal of Nutritional Science
- Vol. 11, e31
A high-fibre personalised dietary advice given via a web tool reduces constipation complaints in adults
Constipation can greatly impact the quality of life (QoL), which can be relieved by dietary fibres; however, preserving a higher fibre intake remains a challenge. We investigated the effects of a personalised dietary advice (PDA) on fibre intake and mild constipation complaints. A total number of twenty-five adults with mild constipation complaints were included in a 4-week observation period followed by a 4-week personalised intervention. The PDA provided high-fibre alternatives via a web tool. In weeks 1, 4 and 8, dietary intake, constipation complaints and QoL were assessed. Furthermore, participants collected a faecal sample at weeks 1, 4 and 8 to determine microbiota diversity and composition, and short-chain fatty acids (SCFA). Participants completed questions daily for 8 weeks regarding abdominal complaints, stool frequency and stool consistency. Fibre intake in week 8 was significantly higher compared to week 1 (Δ= 5·7 ± 6·7 g,P< 0·001) and week 4 (Δ= 5·2 ± 6·4 g,P< 0·001). Constipation severity and QoL significantly improved at week 8 compared to the observation period (P< 0·001). A higher fibre intake significantly reduced constipation severity (β= −0·031 (−0·05; −0·01),P= 0·001) and the QoL (β= −0·022 (−0·04; −0·01),P= 0·009). Stool consistency (P= 0·040) and abdominal pain (P= 0·030) improved significantly during the intervention period (P= 0·040), but stool frequency did not. Average microbial alpha diversity and composition and SCFA concentrations did not change over time, but indicated individual-specific dynamics. Several SCFAs were associated with constipation complaints. To conclude, a PDA effectively increased fibre intake and subsequently reduced constipation complaints, indicating that guided dietary adjustments are important and feasible in the treatment of mild constipation complaints.
- 28 April 2022
- Published by Cambridge University Press (CUP) in Journal of Nutritional Science
- Vol. 11, e31
Open AccessA high-fibre personalised dietary advice given via a web tool reduces constipation complaints in adults
Constipation can greatly impact the quality of life (QoL), which can be relieved by dietary fibres; however, preserving a higher fibre intake remains a challenge. We investigated the effects of a personalised dietary advice (PDA) on fibre intake and mild constipation complaints. A total number of twenty-five adults with mild constipation complaints were included in a 4-week observation period followed by a 4-week personalised intervention. The PDA provided high-fibre alternatives via a web tool. In weeks 1, 4 and 8, dietary intake, constipation complaints and QoL were assessed. Furthermore, participants collected a faecal sample at weeks 1, 4 and 8 to determine microbiota diversity and composition, and short-chain fatty acids (SCFA). Participants completed questions daily for 8 weeks regarding abdominal complaints, stool frequency and stool consistency. Fibre intake in week 8 was significantly higher compared to week 1 (Δ= 5·7 ± 6·7 g,P< 0·001) and week 4 (Δ= 5·2 ± 6·4 g,P< 0·001). Constipation severity and QoL significantly improved at week 8 compared to the observation period (P< 0·001). A higher fibre intake significantly reduced constipation severity (β= −0·031 (−0·05; −0·01),P= 0·001) and the QoL (β= −0·022 (−0·04; −0·01),P= 0·009). Stool consistency (P= 0·040) and abdominal pain (P= 0·030) improved significantly during the intervention period (P= 0·040), but stool frequency did not. Average microbial alpha diversity and composition and SCFA concentrations did not change over time, but indicated individual-specific dynamics. Several SCFAs were associated with constipation complaints. To conclude, a PDA effectively increased fibre intake and subsequently reduced constipation complaints, indicating that guided dietary adjustments are important and feasible in the treatment of mild constipation complaints.
- Open Access
- 4 April 2022
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 129 (2) , 231-239
Web-based dietary assessment and advice helps inflammatory bowel disease patients to improve their diet quality
Time to evaluate diet quality and give dietary advice is limited in clinical inflammatory bowel disease (IBD) practice. The Eetscore is a web-based tool that assesses diet quality according to the Dutch dietary guidelines and provides personalised dietary advice. We aimed to assess diet quality of IBD patients using the Eetscore and to study changes in diet quality, health-related quality of life (HRQoL) and clinical disease activity over time. A prospective cohort study was performed in 195 adult IBD patients. Participants were invited to fill out questionnaires (Eetscore-FFQ, short Inflammatory Bowel Disease Questionnaire and Patient Harvey Bradshaw Index/Patient Simple Clinical Colitis Activity Index) at baseline and after 1 and 4 months. The Eetscore calculates diet quality based on sixteen food components (ten points per component, total score 0–160; the higher the better) and provides dietary advice per component based on the assessment. At baseline, mean diet quality was 98 (sd 19). Diet quality was positively associated with age, female sex and level of education. Component scores were highest for red meat, wholegrain products and sweetened beverages, and lowest for legumes, nuts and processed meat. Over time, diet quality increased to 107 (sd 21) at 4 months (P < 0·001). Each ten-point improvement in diet quality was associated with an increase in HRQoL (β = 0·4 (95 % CI (0·02, 0·7), P = 0·04). Clinical disease activity did not change. In conclusion, diet quality of IBD patients significantly improved following personalised dietary advice of the Eetscore. Improvement of diet quality was associated with a slight improvement in HRQoL. The Eetscore is a practical and useful tool to monitor and support a healthy diet in IBD patients.
- 4 April 2022
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 129 (2) , 231-239
Open AccessWeb-based dietary assessment and advice helps inflammatory bowel disease patients to improve their diet quality
Time to evaluate diet quality and give dietary advice is limited in clinical inflammatory bowel disease (IBD) practice. The Eetscore is a web-based tool that assesses diet quality according to the Dutch dietary guidelines and provides personalised dietary advice. We aimed to assess diet quality of IBD patients using the Eetscore and to study changes in diet quality, health-related quality of life (HRQoL) and clinical disease activity over time. A prospective cohort study was performed in 195 adult IBD patients. Participants were invited to fill out questionnaires (Eetscore-FFQ, short Inflammatory Bowel Disease Questionnaire and Patient Harvey Bradshaw Index/Patient Simple Clinical Colitis Activity Index) at baseline and after 1 and 4 months. The Eetscore calculates diet quality based on sixteen food components (ten points per component, total score 0–160; the higher the better) and provides dietary advice per component based on the assessment. At baseline, mean diet quality was 98 (sd 19). Diet quality was positively associated with age, female sex and level of education. Component scores were highest for red meat, wholegrain products and sweetened beverages, and lowest for legumes, nuts and processed meat. Over time, diet quality increased to 107 (sd 21) at 4 months (P < 0·001). Each ten-point improvement in diet quality was associated with an increase in HRQoL (β = 0·4 (95 % CI (0·02, 0·7), P = 0·04). Clinical disease activity did not change. In conclusion, diet quality of IBD patients significantly improved following personalised dietary advice of the Eetscore. Improvement of diet quality was associated with a slight improvement in HRQoL. The Eetscore is a practical and useful tool to monitor and support a healthy diet in IBD patients.